Pharsight

Kowa Co patents expiration

1. Livalo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557993 KOWA CO Crystalline forms of pitavastatin calcium
Feb, 2024

(4 months from now)

US7022713 KOWA CO Hyperlipemia therapeutic agent
Feb, 2024

(4 months from now)

US8557993

(Pediatric)

KOWA CO Crystalline forms of pitavastatin calcium
Aug, 2024

(10 months from now)

US7022713

(Pediatric)

KOWA CO Hyperlipemia therapeutic agent
Aug, 2024

(10 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 16, 2022
Pediatric Exclusivity (PED) Nov 16, 2022

Drugs and Companies using PITAVASTATIN CALCIUM ingredient

Market Authorisation Date: 03 August, 2009

Treatment: Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemi...

Dosage: TABLET;ORAL

How can I launch a generic of LIVALO before it's drug patent expiration?
More Information on Dosage

LIVALO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic